{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:59:16Z","timestamp":1781884756626,"version":"3.54.5"},"reference-count":46,"publisher":"American Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate the clinical, economic, and social benefits and costs of evidence-based obesity treatment among commercially insured adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Using a Markov-based microsimulation model, we projected 5-year clinical and economic outcomes of intensive lifestyle management, obesity medications, and metabolic\/bariatric surgery, drawing on data from clinical trials, national surveys, and economic studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>This analysis focused on 47.3 million commercially insured adults with obesity who lacked access to treatment through existing clinical pathways. Over 5 years, cumulative medical savings per person ranged from $2,908 for lifestyle intervention to $2,450\u2013$7,304 for obesity medications and $12,001 for surgery among adults without preexisting diabetes or cardiovascular disease. At the population level, access to treatment would yield 5-year benefits of $9.7 billion in medical savings, $25.8 billion in productivity gains, $38.8 billion in quality-of-life value, and $29.6 billion in mortality-reduction benefits, requiring $44.7 billion in total investment. Combined benefits produced net social value of $59.1 billion, with a $2.35 return per dollar invested and positive returns as early as the second year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Obesity treatment generates substantial social benefits through improved health outcomes and productivity gains. Medical and disability cost savings and workplace productivity improvements combined could recover 81% of treatment investment. Employees effectively finance coverage through premiums and reduced wages, and comprehensive benefit design that includes health outcomes and quality-of-life improvements more accurately reflects societal treatment value. Coverage decisions based solely on employer economic returns underestimate the full societal value of expanding coverage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title\/>\n                  <\/jats:sec>","DOI":"10.2337\/doci25-0006","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T13:01:36Z","timestamp":1780837296000},"page":"320-329","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":0,"title":["Benefits and Costs of Treating Obesity Among Adults in Commercial Insurance Plans"],"prefix":"10.2337","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-9401","authenticated-orcid":false,"given":"Timothy M.","family":"Dall","sequence":"first","affiliation":[{"name":"GlobalData Plc 1 , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[{"name":"GlobalData Plc 1 , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvi","family":"Sapra","sequence":"additional","affiliation":[{"name":"GlobalData Plc 1 , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ferguson","sequence":"additional","affiliation":[{"name":"American Diabetes Association 2 , Arlington, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Hafida","sequence":"additional","affiliation":[{"name":"American Diabetes Association 2 , Arlington, VA"},{"name":"Boston University School of Medicine 3 , Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1765-2391","authenticated-orcid":false,"given":"Tia","family":"Livingston","sequence":"additional","affiliation":[{"name":"GlobalData Plc 1 , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Moody","sequence":"additional","affiliation":[{"name":"GlobalData Plc 1 , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1217-4916","authenticated-orcid":false,"given":"Nuha A.","family":"ElSayed","sequence":"additional","affiliation":[{"name":"American Diabetes Association 2 , Arlington, VA"},{"name":"Harvard Medical School 4 , Boston, MA"},{"name":"Diabetes Education For All Foundation 6 , New York, NY"},{"name":"Supercharged Scientific 7 , Wellesley, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raveendhara R.","family":"Bannuru","sequence":"additional","affiliation":[{"name":"American Diabetes Association 2 , Arlington, VA"},{"name":"Harvard Medical School 4 , Boston, MA"},{"name":"Tufts University School of Medicine 5 , Boston, MA"},{"name":"Diabetes Education For All Foundation 6 , New York, NY"},{"name":"Supercharged Scientific 7 , Wellesley, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,6,7]]},"reference":[{"key":"2026061911362150600_B1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.gtc.2023.03.006","article-title":"Health complications of obesity: 224 obesity-associated comorbidities from a mechanistic perspective","volume":"52","author":"Yuen","year":"2023","journal-title":"Gastroenterol Clin North Am"},{"key":"2026061911362150600_B2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41387-024-00352-9","article-title":"Assessing the economic impact of obesity and overweight on employers: identifying opportunities to improve work force health and well-being","volume":"14","author":"Dall","year":"2024","journal-title":"Nutr Diabetes"},{"key":"2026061911362150600_B3","unstructured":"Kaiser Family Foundation\n          . 2025 Employer Health Benefits Survey. Accessed 22 October 2025. Available from https:\/\/www.kff.org\/health-costs\/2025-employer-health-benefits-survey\/#55d346a7-5bff-4d99-840c-a793b6a03320"},{"key":"2026061911362150600_B4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061911362150600_B5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2337\/doci25-0004","article-title":"Estimating the health, economic, and social benefits of obesity treatment using microsimulation modeling","volume":"1","author":"Chen","year":"2026","journal-title":"Diabetes, Obesity, and CardioMetabolic CARE"},{"key":"2026061911362150600_B6","doi-asserted-by":"crossref","first-page":"SP430","DOI":"10.37765\/ajmc.2024.89549","article-title":"Modeling the economic value of cardiometabolic virtual-first care programs","volume":"30","author":"Noble","year":"2024","journal-title":"Am J Manag Care"},{"key":"2026061911362150600_B7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/26350106221100779","article-title":"Impact of a digitally enhanced diabetes self-management program on glycemia and medical costs","volume":"48","author":"Chen","year":"2022","journal-title":"Sci Diabetes Self Manag Care"},{"key":"2026061911362150600_B8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.amepre.2014.10.003","article-title":"Value of lifestyle intervention to prevent diabetes and sequelae","volume":"48","author":"Dall","year":"2015","journal-title":"Am J Prev Med"},{"key":"2026061911362150600_B9","unstructured":"Centers for Disease Control and Prevention\n          . Adult BMI Categories. Accessed 11 November 2025. Available from https:\/\/www.cdc.gov\/bmi\/adult-calculator\/bmi-categories.html"},{"key":"2026061911362150600_B10","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.5888\/pcd20.230005","article-title":"State-specific prevalence of severe obesity among adults in the US using bias correction of self-reported body mass index","volume":"20","author":"Zhao","year":"2023","journal-title":"Prev Chronic Dis"},{"key":"2026061911362150600_B11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/doci25-0008","article-title":"Pharmacologic treatment of obesity in adults: standards of care in overweight and obesity","volume":"1","author":"American Diabetes Association Professional Practice Committee for Obesity","year":"2026","journal-title":"Diabetes, Obesity, and CardioMetabolic CARE"},{"key":"2026061911362150600_B12","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases\n          . Potential Candidates for Weight-loss Surgery. Accessed 4 March 2026. Available from https:\/\/www.niddk.nih.gov\/health-information\/weight-management\/bariatric-surgery\/potential-candidates#:~:text=A%20medical%20expert%2C%20like%20a%20doctor%2C%20is,control%20with%20medical%20treatments%20and%20lifestyle%20changes"},{"key":"2026061911362150600_B13","doi-asserted-by":"crossref","first-page":"2055207620918715","DOI":"10.1177\/2055207620918715","article-title":"Weighing the odds: assessing underdiagnosis of adult obesity via electronic medical record problem list omissions","volume":"6","author":"Kapoor","year":"2020","journal-title":"Digit Health"},{"key":"2026061911362150600_B14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1037\/amp0000517","article-title":"Lifestyle modification approaches for the treatment of obesity in adults","volume":"75","author":"Wadden","year":"2020","journal-title":"Am Psychol"},{"key":"2026061911362150600_B15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/oby.20662","article-title":"Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study","volume":"22","author":"Look AHEAD Research Group","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"2026061911362150600_B16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7326\/M18-1605","article-title":"Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program outcomes study","volume":"170","author":"Apolzan","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026061911362150600_B17","unstructured":"Kearsley\n              A\n            \n          . HHS Standard Values for Regulatory Analysis, 2024. Accessed 16 May 2024. Available from https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/cd2a1348ea0777b1aa918089e4965b8c\/standard-ria-values.pdf"},{"key":"2026061911362150600_B18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2337\/dc20-0358","article-title":"Within-trial cost-effectiveness of a structured lifestyle intervention in adults with overweight\/obesity and type 2 diabetes: results from the Action for Health in Diabetes (Look AHEAD) study","volume":"44","author":"Zhang","year":"2021","journal-title":"Diabetes Care"},{"key":"2026061911362150600_B19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026061911362150600_B20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis","volume":"30","author":"Ansari","year":"2024","journal-title":"Endocr Pract"},{"key":"2026061911362150600_B21","unstructured":"The White House\n          . Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients. Accessed 11 November 2025. Available from https:\/\/www.whitehouse.gov\/fact-sheets\/2025\/11\/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients"},{"key":"2026061911362150600_B22","unstructured":"Abt Associates\n          . Cost of Dispensing Study. Accessed 22 October 2022. Available from https:\/\/www.nacds.org\/pdfs\/pharmacy\/2020\/NACDS-NASP-NCPA-COD-Report-01-31-2020-Final.pdf"},{"key":"2026061911362150600_B23","unstructured":"American Society for Metabolic and Bariatric Surgery\n          . Estimate of Bariatric Surgery Numbers, 2011-2022. Accessed 16 May 2024. Available from https:\/\/asmbs.org\/resources\/estimate-of-bariatric-surgery-numbers\/"},{"key":"2026061911362150600_B24","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s11695-016-2533-1","article-title":"Milestone weight loss goals (weight normalization and remission of obesity) after gastric bypass surgery: long-term results from the University of Michigan","volume":"27","author":"Lager","year":"2017","journal-title":"Obes Surg"},{"key":"2026061911362150600_B25","unstructured":"American Society\n            for Metabolic and Bariatric Surgery\n          , American College of Surgeons. Optimal Resources for Metabolic and Bariatric Surgery: 2019 Standards\u2014Revised. Accessed 16 May 2024. Available from https:\/\/www.facs.org\/media\/fguhte1t\/2022_cm_mbsaqip_standards_final_linked-toc.pdf"},{"key":"2026061911362150600_B26","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/oby.20529","article-title":"Clinical factors associated with weight loss outcomes after Roux-en-Y gastric bypass surgery","volume":"22","author":"Still","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"2026061911362150600_B27","doi-asserted-by":"crossref","first-page":"e2148317","DOI":"10.1001\/jamanetworkopen.2021.48317","article-title":"Estimated cost-effectiveness of medical therapy, sleeve gastrectomy, and gastric bypass in patients with severe obesity and type 2 diabetes","volume":"5","author":"Lauren","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026061911362150600_B28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jamasurg.2015.5501","article-title":"Association of patient age at gastric bypass surgery with long-term all-cause and cause-specific mortality","volume":"151","author":"Davidson","year":"2016","journal-title":"JAMA Surg"},{"key":"2026061911362150600_B29","unstructured":"Social Security Administration\n          . Actuarial Life Table. Accessed 11 September 2024. Available from https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html"},{"key":"2026061911362150600_B30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2458-9-88","article-title":"The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis","volume":"9","author":"Guh","year":"2009","journal-title":"BMC Public Health"},{"key":"2026061911362150600_B31","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2337\/dc11-2478","article-title":"Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from Translating Research Into Action for Diabetes (TRIAD)","volume":"35","author":"Zhang","year":"2012","journal-title":"Diabetes Care"},{"key":"2026061911362150600_B32","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0272989X06290495","article-title":"Preference-based EQ-5D index scores for chronic conditions in the United States","volume":"26","author":"Sullivan","year":"2006","journal-title":"Med Decis Making"},{"key":"2026061911362150600_B33","doi-asserted-by":"crossref","first-page":"e184587","DOI":"10.1001\/jamanetworkopen.2018.4587","article-title":"Association of obesity with mortality over 24 years of weight history: findings from the Framingham Heart Study","volume":"1","author":"Xu","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2026061911362150600_B34","unstructured":"Centers Disease Control and Prevention, National Center for Health Statistics. CDC WONDER 2018-2023 Mortality. Accessed 24 June 2025. Available from https:\/\/wonder.cdc.gov\/wonder\/help\/main.html#WhatisWONDER"},{"key":"2026061911362150600_B35","unstructured":"National Cancer Institute\n          . SEER: Surveillance, Epidemiology, and End Results Program. Accessed 18 June 2025. Available from https:\/\/seer.cancer.gov"},{"key":"2026061911362150600_B36","unstructured":"Institute for Clinical and Economic Review\n          . ICER\u2019s Reference Case for Economic Evaluations: Elements and Rationale. Accessed 9 September 2025. Available from https:\/\/icer.org\/wp-content\/uploads\/2024\/02\/Reference-Case-4.3.25.pdf"},{"key":"2026061911362150600_B37","unstructured":"FAIRHealth\n          . Obesity and GLP-1 Drugs: A Claims-Based Analysis. Accessed 9 August 2025. Available from https:\/\/s3. amazonaws.com\/media2.fairhealth.org\/whitepaper\/asset\/Obesity%20and%20GLP-1%20Drugs%20-%20A%20FAIR%20Health%20White%20Paper.pdf"},{"key":"2026061911362150600_B38","unstructured":"Congressional Budget Office\n          . How Would Authorizing Medicare to Cover Anti-Obesity Medications Affect the Federal Budget? Accessed 11 December 2024. Available from https:\/\/www.cbo.gov\/system\/files\/2024-10\/60441-medicare-coverage-obesity.pdf"},{"key":"2026061911362150600_B39","unstructured":"Blue Health Intelligence\n          . Real-World Trends in GLP-1 Treatment Persistence and Prescribing for Weight Management. Accessed 9 August 2025. Available from https:\/\/www.bcbs.com\/media\/pdf\/BHI_Issue_Brief_GLP1_Trends.pdf"},{"key":"2026061911362150600_B40","first-page":"860","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","author":"Gleason","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"2026061911362150600_B41","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.2337\/dc19-2366","article-title":"Retention among participants in the National Diabetes Prevention Program Lifestyle Change Program, 2012\u20132017","volume":"43","author":"Cannon","year":"2020","journal-title":"Diabetes Care"},{"key":"2026061911362150600_B42","doi-asserted-by":"crossref","first-page":"103796","DOI":"10.1016\/j.eclinm.2026.103796","article-title":"Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression","volume":"93","author":"Budini","year":"2026","journal-title":"EClinicalMedicine"},{"key":"2026061911362150600_B43","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1377\/hlthaff.2023.01489","article-title":"Cost-effectiveness and health impact of increasing emergency department pediatric readiness in the US","volume":"43","author":"Weyant","year":"2024","journal-title":"Health Aff (Millwood)"},{"key":"2026061911362150600_B44","unstructured":"American Medical Association\n          . AMA Urges Insurance Coverage Parity for Emerging Obesity Treatment Options. Accessed 4 June 2025. Available from https:\/\/www.ama-assn.org\/press-center\/ama-press-releases\/ama-urges-insurance-coverage-parity-emerging-obesity-treatment"},{"key":"2026061911362150600_B45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026061911362150600_B46","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Diabetes Obesity and Cardiometabolic CARE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article-pdf\/1\/3\/320\/881934\/docmi250006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article-pdf\/1\/3\/320\/881934\/docmi250006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:36:32Z","timestamp":1781883392000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article\/1\/3\/320\/170056\/Benefits-and-Costs-of-Treating-Obesity-Among"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,7]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/doci25-0006","relation":{},"ISSN":["3067-3518","3067-3534"],"issn-type":[{"value":"3067-3518","type":"print"},{"value":"3067-3534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}